Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study.
Adrenergic alpha-1 Receptor Antagonists
/ therapeutic use
Aged
Drug Resistance
Drug Therapy, Combination
Humans
Lower Urinary Tract Symptoms
/ drug therapy
Male
Middle Aged
Pelvic Pain
/ drug therapy
Plant Extracts
/ therapeutic use
Pollen
/ chemistry
Prospective Studies
Prostatitis
/ drug therapy
Tadalafil
/ therapeutic use
Treatment Outcome
Urodynamics
cernitin pollen extract
chronic pelvic pain syndrome
chronic prostatitis
chronic prostatitis symptom index
tadalafil
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
13
05
2020
revised:
03
06
2020
accepted:
28
06
2020
pubmed:
11
7
2020
medline:
13
1
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
To compare the efficacy of cernitin pollen extract (cernitin) or tadalafil for treating persistent chronic pelvic pain despite α1-blocker monotherapy in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and lower urinary tract symptoms (LUTS). A total of 100 patients with refractory CP/CPPS despite ongoing α1-blocker monotherapy were randomized to receive add-on therapy with either cernitin (4 capsules/day) or tadalafil (5 mg/d) for 12 weeks. At week 12, changes from baseline in the patients' CP/CPPS, LUTS, and voiding function, as assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and uroflowmetry, respectively, were compared between the groups. The final analysis included 42 and 45 patients in the cernitin and tadalafil groups, respectively. Although the NIH-CPSI total, NIH-CPSI pain sub-score, and NIH-CPSI quality of life sub-score significantly improved in both groups, the cernitin (vs tadalafil) group showed significantly greater improvements in the NIH-CPSI total score (-6.8 vs -4.6; P = .02) and NIH-CPSI pain sub-score (-4.1 vs -1.5; P < .001). Half (50%) of the patients in the cernitin group showed a reduction greater than 50% in their NIH-CPSI pain sub-score; in the tadalafil group, only four patients (8.9%) showed ≥50% improvement (P < .001). In contrast, the improvement in LUTS was significantly superior in the tadalafil group. Both cernitin and tadalafil significantly ameliorated chronic pelvic pain in patients with refractory CP/CPPS. The add-on of cernitin was more effective than tadalafil for pelvic pain and discomfort.
Substances chimiques
Adrenergic alpha-1 Receptor Antagonists
0
Plant Extracts
0
Tadalafil
742SXX0ICT
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1994-2002Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441.
Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 2006;355:1690-1698.
Schaeffer AJ, Datta NS, Fowler JE Jr, et al. Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urology. 2002;60:1-4.
Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236-237.
Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999;54:229-233.
Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int. 2007;100:1307-1311.
Franco JVA, Turk T, Jung JH, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2020;125:490-496.
Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment ofchronic bacterial prostatitis and chronic prostatitis/chronic pelvic painsyndrome: a consensus guideline. BJU Int. 2015;116:509-525.
Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical phenotypingin chronic prostatitis/chronic pelvic pain syndrome and interstitialcystitis: a management strategy for urologic chronic pelvic painsyndromes. Prostate Cancer Prostatic Dis. 2009;12:177-183.
Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116:509-525.
Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brähler E, Weidner W. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56:544-551.
Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292-301.
Kurita M, Yamaguchi H, Okamoto K, Kotera T, Oka M. Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain. Prostate. 2018;78:1157-1165.
Sugimoto M, Zhang X, Ueda N, et al. A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. BMC Urol. 2019;19:99.
Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999;162:369-375.
Kamijo T, Sato S, Kitamura T. Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Prostate. 2001;49:122-131.
Cai T, Wagenlehner FM, Luciani LG, et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Exp Ther Med. 2014;8:1032-1038.
Morelli A, Comeglio P, Filippi S, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2013;73:428-441.
Okamoto K, Kurita M, Yamaguchi H, Numakura Y, Oka M. Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis. Prostate. 2018;78:707-713.
Benelli A, Mariani S, Varca V, Gregori A, Barrese F, Cappa M. Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome. Ther Adv Urol. 2018;10:377-381.
Hiramatsu I, Tsujimura A, Soejima M, et al. Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. Int J Urol. 2020;27:53-57.
Nickel JC. Is chronic prostatitis/chronic pelvic pain syndrome an infectious disease of the prostate? Investig Clin Urol. 2017;58:149-151.
Togo Y, Ichioka D, Miyazaki J, et al. Japanese Research Group for Urinary Tract Infection (. Oral administration of cernitin pollen extract (Cernilton®) for 30 days might be useful to avoid unnecessary biopsy in prostate biopsy candidates: a preliminary study. Int J Urol. 2018;25:479-485.